Indaptus Therapeutics (INDP) Stock Price, News & Analysis

Company Overview

Indaptus Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors. The company is also exploring applications in antiviral immunotherapies, reflecting the versatility of its platform. By combining advanced engineering techniques with scalable manufacturing processes, Indaptus aims to deliver off-the-shelf therapies to patients with unmet medical needs.

Headquartered in the United States, Indaptus collaborates with academic institutions and contract research organizations to advance discovery and clinical translation. Since its inception, the company has established state-of-the-art research and development facilities to support process development, preclinical evaluation, and future clinical manufacturing. Led by a management team with deep experience in cell and gene therapy development, Indaptus is positioned to move its lead programs into early-phase clinical trials and expand its strategic partnerships in the biopharmaceutical industry.

Key Stats

• Today's Range: $1.10 to $1.16
• 50-Day Range: $0.94 to $3.71
• 52-Week Range: $0.92 to $8.57
• Volume: 66,644 shs
• Average Volume: 515,883 shs
• Market Capitalization: $150.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Indaptus Therapeutics Stock Analysis - MarketRank™

Indaptus Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 854th out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Indaptus Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Indaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Indaptus Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indaptus Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Indaptus Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Indaptus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indaptus Therapeutics has recently increased by 32.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indaptus Therapeutics does not currently pay a dividend.

Dividend Growth

Indaptus Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.63

News Sentiment

Indaptus Therapeutics has a news sentiment score of 1.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Indaptus Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.94% of the stock of Indaptus Therapeutics is held by insiders.

Percentage Held by Institutions

7.06% of the stock of Indaptus Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/01/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INDP
• CIK: 1857044
• Web: intecpharma.com
• Phone: (646) 427-2727
• Fax: 972-2586-9176
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($6.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -302.89%
• Return on Assets: -203.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.49
• Quick Ratio: 19.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.40 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 133,240,000
• Free Float: 119,998,000
• Market Cap: $151.23 million
• Optionable: Not Optionable
• Beta: 1.18